Pituitary deficiency after aneurysmal subarachnoid hemorrhage

Detalhes bibliográficos
Autor(a) principal: Pereira, Julio Leonardo Barbosa
Data de Publicação: 2013
Outros Autores: Albuquerque, Lucas Alverne Freitas de, Dellaretti, Marcos, de Carvalho, Gervásio Teles Cardoso, Vieira Jr, Gerival, Brochado, Vitor Michelstaedter, Drummond, Austen Venâncio, Morais, Joyce Espeschit de, Ferreira, Leticia Maia, Miranda, Paulo Augusto Carvalho, Sousa, Atos Alves de
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Clinics
Texto Completo: https://www.revistas.usp.br/clinics/article/view/76859
Resumo: OBJECTIVE: Aneurysmal subarachnoid hemorrhage puts patients at high risk for the development of pituitary insufficiency. We evaluated the incidence of pituitary dysfunction in these patients and its correlation with clinical outcome. METHODS: Pituitary function was tested in 66 consecutive patients in the first 15 days after aneurysmal subarachnoid hemorrhage. The following were measured in all patients: thyroid-stimulating hormone, free thyroxine, triiodothyronine, luteinizing hormone, follicle-stimulating hormone, total testosterone (in males), estradiol (in females), prolactin, serum cortisol, plasma adrenocorticotropic hormone, growth hormone and insulin growth factor. RESULTS: The endocrine assessment was made at a mean of 7.4 days (standard deviation ±6.6) after subarachnoid hemorrhage. Forty-four (66.7%) female and 22 (33.3%) male patients were evaluated. Thirty-nine patients (59.1%) had some type of pituitary dysfunction. Follicle-stimulating hormone/luteinizing hormone deficiency was the most frequent disorder (34.8%), followed by growth hormone/insulin growth factor (28.7%), adrenocorticotropic hormone (18.1%) and thyroid-stimulating hormone (9%). Seventeen (25.7%) patients showed deficiencies in more than one axis. A greater incidence of hormone deficiency was observed in patients with a Glasgow Coma Scale score ≤13 (t test, p = 0.008), Hunt-Hess grade ≥4 (t test, p;0.05) with increased hospitalization or clinical outcome. CONCLUSION: Pituitary dysfunction was identified in a substantial portion of patients with previous aneurysmal subarachnoid hemorrhage, but no association was found between this dysfunction and poor clinical outcome.
id USP-19_19c705236d894452b8b7711fdd2bb2d6
oai_identifier_str oai:revistas.usp.br:article/76859
network_acronym_str USP-19
network_name_str Clinics
repository_id_str
spelling Pituitary deficiency after aneurysmal subarachnoid hemorrhageOBJECTIVE: Aneurysmal subarachnoid hemorrhage puts patients at high risk for the development of pituitary insufficiency. We evaluated the incidence of pituitary dysfunction in these patients and its correlation with clinical outcome. METHODS: Pituitary function was tested in 66 consecutive patients in the first 15 days after aneurysmal subarachnoid hemorrhage. The following were measured in all patients: thyroid-stimulating hormone, free thyroxine, triiodothyronine, luteinizing hormone, follicle-stimulating hormone, total testosterone (in males), estradiol (in females), prolactin, serum cortisol, plasma adrenocorticotropic hormone, growth hormone and insulin growth factor. RESULTS: The endocrine assessment was made at a mean of 7.4 days (standard deviation ±6.6) after subarachnoid hemorrhage. Forty-four (66.7%) female and 22 (33.3%) male patients were evaluated. Thirty-nine patients (59.1%) had some type of pituitary dysfunction. Follicle-stimulating hormone/luteinizing hormone deficiency was the most frequent disorder (34.8%), followed by growth hormone/insulin growth factor (28.7%), adrenocorticotropic hormone (18.1%) and thyroid-stimulating hormone (9%). Seventeen (25.7%) patients showed deficiencies in more than one axis. A greater incidence of hormone deficiency was observed in patients with a Glasgow Coma Scale score ≤13 (t test, p = 0.008), Hunt-Hess grade ≥4 (t test, p;0.05) with increased hospitalization or clinical outcome. CONCLUSION: Pituitary dysfunction was identified in a substantial portion of patients with previous aneurysmal subarachnoid hemorrhage, but no association was found between this dysfunction and poor clinical outcome.Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo2013-06-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://www.revistas.usp.br/clinics/article/view/7685910.1590/clin.v68i6.76859Clinics; Vol. 68 No. 6 (2013); 745-749Clinics; v. 68 n. 6 (2013); 745-749Clinics; Vol. 68 Núm. 6 (2013); 745-7491980-53221807-5932reponame:Clinicsinstname:Universidade de São Paulo (USP)instacron:USPenghttps://www.revistas.usp.br/clinics/article/view/76859/80721Pereira, Julio Leonardo BarbosaAlbuquerque, Lucas Alverne Freitas deDellaretti, Marcosde Carvalho, Gervásio Teles CardosoVieira Jr, GerivalBrochado, Vitor MichelstaedterDrummond, Austen VenâncioMorais, Joyce Espeschit deFerreira, Leticia MaiaMiranda, Paulo Augusto CarvalhoSousa, Atos Alves deinfo:eu-repo/semantics/openAccess2014-03-21T19:56:32Zoai:revistas.usp.br:article/76859Revistahttps://www.revistas.usp.br/clinicsPUBhttps://www.revistas.usp.br/clinics/oai||clinics@hc.fm.usp.br1980-53221807-5932opendoar:2014-03-21T19:56:32Clinics - Universidade de São Paulo (USP)false
dc.title.none.fl_str_mv Pituitary deficiency after aneurysmal subarachnoid hemorrhage
title Pituitary deficiency after aneurysmal subarachnoid hemorrhage
spellingShingle Pituitary deficiency after aneurysmal subarachnoid hemorrhage
Pereira, Julio Leonardo Barbosa
title_short Pituitary deficiency after aneurysmal subarachnoid hemorrhage
title_full Pituitary deficiency after aneurysmal subarachnoid hemorrhage
title_fullStr Pituitary deficiency after aneurysmal subarachnoid hemorrhage
title_full_unstemmed Pituitary deficiency after aneurysmal subarachnoid hemorrhage
title_sort Pituitary deficiency after aneurysmal subarachnoid hemorrhage
author Pereira, Julio Leonardo Barbosa
author_facet Pereira, Julio Leonardo Barbosa
Albuquerque, Lucas Alverne Freitas de
Dellaretti, Marcos
de Carvalho, Gervásio Teles Cardoso
Vieira Jr, Gerival
Brochado, Vitor Michelstaedter
Drummond, Austen Venâncio
Morais, Joyce Espeschit de
Ferreira, Leticia Maia
Miranda, Paulo Augusto Carvalho
Sousa, Atos Alves de
author_role author
author2 Albuquerque, Lucas Alverne Freitas de
Dellaretti, Marcos
de Carvalho, Gervásio Teles Cardoso
Vieira Jr, Gerival
Brochado, Vitor Michelstaedter
Drummond, Austen Venâncio
Morais, Joyce Espeschit de
Ferreira, Leticia Maia
Miranda, Paulo Augusto Carvalho
Sousa, Atos Alves de
author2_role author
author
author
author
author
author
author
author
author
author
dc.contributor.author.fl_str_mv Pereira, Julio Leonardo Barbosa
Albuquerque, Lucas Alverne Freitas de
Dellaretti, Marcos
de Carvalho, Gervásio Teles Cardoso
Vieira Jr, Gerival
Brochado, Vitor Michelstaedter
Drummond, Austen Venâncio
Morais, Joyce Espeschit de
Ferreira, Leticia Maia
Miranda, Paulo Augusto Carvalho
Sousa, Atos Alves de
description OBJECTIVE: Aneurysmal subarachnoid hemorrhage puts patients at high risk for the development of pituitary insufficiency. We evaluated the incidence of pituitary dysfunction in these patients and its correlation with clinical outcome. METHODS: Pituitary function was tested in 66 consecutive patients in the first 15 days after aneurysmal subarachnoid hemorrhage. The following were measured in all patients: thyroid-stimulating hormone, free thyroxine, triiodothyronine, luteinizing hormone, follicle-stimulating hormone, total testosterone (in males), estradiol (in females), prolactin, serum cortisol, plasma adrenocorticotropic hormone, growth hormone and insulin growth factor. RESULTS: The endocrine assessment was made at a mean of 7.4 days (standard deviation ±6.6) after subarachnoid hemorrhage. Forty-four (66.7%) female and 22 (33.3%) male patients were evaluated. Thirty-nine patients (59.1%) had some type of pituitary dysfunction. Follicle-stimulating hormone/luteinizing hormone deficiency was the most frequent disorder (34.8%), followed by growth hormone/insulin growth factor (28.7%), adrenocorticotropic hormone (18.1%) and thyroid-stimulating hormone (9%). Seventeen (25.7%) patients showed deficiencies in more than one axis. A greater incidence of hormone deficiency was observed in patients with a Glasgow Coma Scale score ≤13 (t test, p = 0.008), Hunt-Hess grade ≥4 (t test, p;0.05) with increased hospitalization or clinical outcome. CONCLUSION: Pituitary dysfunction was identified in a substantial portion of patients with previous aneurysmal subarachnoid hemorrhage, but no association was found between this dysfunction and poor clinical outcome.
publishDate 2013
dc.date.none.fl_str_mv 2013-06-01
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://www.revistas.usp.br/clinics/article/view/76859
10.1590/clin.v68i6.76859
url https://www.revistas.usp.br/clinics/article/view/76859
identifier_str_mv 10.1590/clin.v68i6.76859
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv https://www.revistas.usp.br/clinics/article/view/76859/80721
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo
publisher.none.fl_str_mv Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo
dc.source.none.fl_str_mv Clinics; Vol. 68 No. 6 (2013); 745-749
Clinics; v. 68 n. 6 (2013); 745-749
Clinics; Vol. 68 Núm. 6 (2013); 745-749
1980-5322
1807-5932
reponame:Clinics
instname:Universidade de São Paulo (USP)
instacron:USP
instname_str Universidade de São Paulo (USP)
instacron_str USP
institution USP
reponame_str Clinics
collection Clinics
repository.name.fl_str_mv Clinics - Universidade de São Paulo (USP)
repository.mail.fl_str_mv ||clinics@hc.fm.usp.br
_version_ 1800222760201355264